The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease

Text [edit]

a string of failures. Years of testing drugs that target amyloid buildup have not yielded significant returns, and may be squeezing out other more promising approaches [Ix4].

Medicare’s finances. Aducanumab is an incredibly expensive treatment, and could undermine an already highly weakened Medicare system.

Reference [edit]

Washington Post. n.d. “The Controversial Approval of an Alzheimer’s Drug Reignites the Battle over the Underlying Cause of the Disease.” https://www.washingtonpost.com/health/2021/07/05/aduhelm-new-alzheimers-drug-amyloid/.